Real patients taking AMVUTTRA® (vutrisiran)

PERSPECTIVE you can count on

Talk with someone who can relate to your journey

You don’t have to navigate ATTR amyloidosis on your own. The Talk to a Patient program is available for people diagnosed with ATTR amyloidosis and their caregivers. The program matches you with a person who is living with ATTR cardiac amyloidosis or hereditary ATTR with polyneuropathy and taking AMVUTTRA® (vutrisiran). They can connect with you by phone and share their perspective as you navigate your path forward.*

How it works

1. Sign Up

Complete the sign-up form below or call 888-537-4021 to get matched with a patient.

2. Schedule a Call

Once matched, someone from the team will reach out by phone and coordinate a time that works for you.

3. Connect & Follow Up

Join a phone call to ask questions, talk through what's on your mind, and hear from someone with firsthand experience.

*Patients are Ambassadors of Alnylam Pharmaceuticals and are compensated for their time. Patients are not medical or mental health professionals and cannot provide medical advice. Please talk to your healthcare provider for medical information.

Fill out the form below to get started

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.